Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer

NCT04739670 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT04739670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04739670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2021
Completion date
September 30, 2025
Enrollment
31 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple negative breast cancer